TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38547135

Group type: EXPERIMENTAL
Intervention: Prolonged daily motion modulated stimulation with a multichannel vestibulocochlear implant (VCI) prototype
Number of subjects: 8

Group type: COMPARATOR
Intervention: Three types of stimulation
Number of subjects: 8
Study: 38547208

Group type: EXPERIMENTAL
Intervention: Single bout of resistance exercise consisting of eight sets of 10 repetitions of unilateral knee extension at 70% of one-repetition maximum.
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Single bout of resistance exercise
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pre-exercise histidine and sarcosine levels
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pre/post-exercise fold change in plasma histidine
Number of subjects: 79
Study: 38547322

Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide (20 mg/ml, 1 ml)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo (sodium chloride, 1 ml)
Number of subjects: 249
Study: 38547425

Group type: EXPERIMENTAL
Intervention: Mosunetuzumab
Number of subjects: 0
Study: 38547453

Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated catheter-directed thrombolysis (UA-CDT)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 152
Study: 38547892

Group type: EXPERIMENTAL
Intervention: Gedatolisib plus palbociclib and endocrine therapy (Letrozole for group A, Fulvestrant for groups B-D)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Gedatolisib plus palbociclib and endocrine therapy
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Treatment-related serious adverse events
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events
Number of subjects: 103
Study: 38547891

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 6.4 mg/kg (cohort 1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan 5.4 mg/kg (cohort 1A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (both cohorts)
Number of subjects: 90
Study: 38547893

Group type: EXPERIMENTAL
Intervention: LOAd703 combined with nab-paclitaxel (125 mg/m2) and gemcitabine
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LOAd703
Number of subjects: 21
Study: 38547895

Group type: EXPERIMENTAL
Intervention: Atezolizumab (800 mg intravenously every 2 weeks up to 1 year) plus modified docetaxel, cisplatin, and fluorouracil (mDCF) (eight cycles of 40 mg per m2 docetaxel, 75 mg per m2 cisplatin, and 750 mg per m2 fluorouracil)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus mDCF
Number of subjects: 97

Group type: COMPARATOR
Intervention: mDCF
Number of subjects: 97
Study: 38547961

Group type: EXPERIMENTAL
Intervention: Tirzepatide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38547955

Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography (CCTA)
Number of subjects: 797

Group type: COMPARATOR
Intervention: Invasive Coronary Angiography (ICA)
Number of subjects: 797
Study: 38548067

Group type: EXPERIMENTAL
Intervention: FAST (FibroScan-aspartate aminotransferase [AST])
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: MAST (MRI-AST)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: MEFIB (magnetic resonance elastography [MRE] plus FIB-4)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: FNI (fibrotic NASH index)
Number of subjects: 330
Study: 38548135

Group type: EXPERIMENTAL
Intervention: Switching between food items during meals
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Switching between food items during eating in the absence of hunger (EAH)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Consistency of switching behavior across meals
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Consistency of switching behavior across EAH paradigms
Number of subjects: 88
Study: 38548365

Group type: EXPERIMENTAL
Intervention: Daily diary ratings of emotional state and pain severity (children only) at baseline and post
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Questionnaires on quality of life, social support, sleep, and symptoms of anxiety and depression at each time point
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Generalised linear regression models for predicting development of CPSP
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: K-means classification method for longitudinal data
Number of subjects: 280
Study: 38548367

Group type: EXPERIMENTAL
Intervention: Preadmission non-polypharmacy (<5 medications)
Number of subjects: 85942

Group type: EXPERIMENTAL
Intervention: Preadmission polypharmacy (5-10 medications)
Number of subjects: 85942

Group type: EXPERIMENTAL
Intervention: Preadmission hyperpolypharmacy (>10 medications)
Number of subjects: 85942

Group type: EXPERIMENTAL
Intervention: New postdischarge polypharmacy
Number of subjects: 85942

Group type: EXPERIMENTAL
Intervention: New postdischarge hyperpolypharmacy
Number of subjects: 85942

Group type: EXPERIMENTAL
Intervention: Higher level of medication use
Number of subjects: 85942
Study: 38548404

Group type: EXPERIMENTAL
Intervention: Low dose azacitidine 50 mg/m plus venetoclax
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Low dose azacitidine plus venetoclax
Number of subjects: 35
Study: 38548406

Group type: EXPERIMENTAL
Intervention: Macitentan
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 38548524

Group type: EXPERIMENTAL
Intervention: patisiran 0.3 mg/kg intravenously every 3 weeks for 18 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 38548948

Group type: EXPERIMENTAL
Intervention: Velvet-soft PVC tube (group V)
Number of subjects: 149

Group type: COMPARATOR
Intervention: PVC tube (group P)
Number of subjects: 149

Group type: COMPARATOR
Intervention: PVC tube attached to a rubber catheter (group PR)
Number of subjects: 149
Study: 38549070

Group type: EXPERIMENTAL
Intervention: Bandage contact lenses (BCLs)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Gauze (control group)
Number of subjects: 69
Study: 38549121

Group type: EXPERIMENTAL
Intervention: Eptinezumab
Number of subjects: 0
Study: 38549122

Group type: EXPERIMENTAL
Intervention: LOCI plus MBC training and technical assistance
Number of subjects: 21

Group type: COMPARATOR
Intervention: MBC training and technical assistance only
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: LOCI
Number of subjects: 21
Study: 38549128

Group type: EXPERIMENTAL
Intervention: Peripheral nerve stimulation (PNS)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Best medical treatment (BMT)
Number of subjects: 90
Study: 38549745

Group type: EXPERIMENTAL
Intervention: E304i food additive
Number of subjects: 0
Study: 38549835

Group type: EXPERIMENTAL
Intervention: FBN (Feature-Based Network) models with 32, 64, 128, and 256 gray levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: FBS (Feature-Based Segmentation) models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parameter-optimized model (FBN = 64 and FBN = 128)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier analyses
Number of subjects: 0
Study: 38550293

Group type: EXPERIMENTAL
Intervention: ECD-focused parenting and nutrition education delivered by local Community Health Workers (CHWs) for one year, with fortnightly home visits.
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 599
Study: 38550328

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccine intervention delivery
Number of subjects: 0
Study: 38550605

Group type: EXPERIMENTAL
Intervention: 2-week arm (34Gy in 10 fractions over 2 weeks)
Number of subjects: 1121

Group type: COMPARATOR
Intervention: 3-week arm (35Gy in 15 fractions over 3 weeks)
Number of subjects: 1121
Study: 38550709

Group type: EXPERIMENTAL
Intervention: Interpectoral and pectoserratus plane block (IPP/PSP)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Local anesthetic infiltration
Number of subjects: 57
Study: 38550899

Group type: EXPERIMENTAL
Intervention: LIVE intervention (multicomponent intervention implemented by municipal coordinators over a 6-month period)
Number of subjects: 280
Study: 38551015

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 1720

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1720
Study: 38551365

Group type: EXPERIMENTAL
Intervention: Cocaine self-administration behavior; specific dosage and duration not available.
Number of subjects: 0
Study: 38551394

Group type: EXPERIMENTAL
Intervention: TPST-1120 monotherapy
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: TPST-1120 in combination with nivolumab
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study: 38551501

Group type: EXPERIMENTAL
Intervention: CAR-GD2 T-cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tazemetostat (EZH2 inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AP1903 (dimerizing drug)
Number of subjects: 0
Study: 38551522

Group type: EXPERIMENTAL
Intervention: HF cardiologists and family doctors' estimates of patient 1-year mortality
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: Female HF cardiologists making predictions on male patients
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: HF cardiologist estimates in Black patients
Number of subjects: 1643

Group type: EXPERIMENTAL
Intervention: High-confidence estimates
Number of subjects: 1643
Study: 38551563

Group type: EXPERIMENTAL
Intervention: Culprit lesion PCI before complete CAG
Number of subjects: 184

Group type: COMPARATOR
Intervention: Complete CAG followed by culprit lesion PCI
Number of subjects: 184
Study: 38551588

Group type: EXPERIMENTAL
Intervention: 2 informational emails encouraging households to switch to CSR plans
Number of subjects: 42470

Group type: COMPARATOR
Intervention: No-email control group
Number of subjects: 42470
Study: 38551617

Group type: EXPERIMENTAL
Intervention: Self-guided digital mental health intervention (Happify for Teens) for 12 weeks
Number of subjects: 303

Group type: COMPARATOR
Intervention: Waitlist control for 12 weeks
Number of subjects: 303
Study: 38551689

Group type: EXPERIMENTAL
Intervention: Anticholinergic burden (ACB)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Polypharmacy (PP)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Potential drug-drug interactions (DDIs)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Cumulative anticholinergic burden (ACB)
Number of subjects: 636
Study: 38551773

Group type: EXPERIMENTAL
Intervention: Exercise interventions (specific types not detailed), duration: 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-functioning group with low symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various algorithms (Random Forest, Logistic Regression, Ridge Regression)
Number of subjects: 0
Study: 38551807

Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 43
Study: 38551806

Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 13
Study: 38551926

Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-stunted children
Number of subjects: 200
Study: 38551934

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA/stenting) in TRAS group (N = 20)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Clinical treatment in TNS group (N = 14)
Number of subjects: 34
Study: 38551973

Group type: EXPERIMENTAL
Intervention: Full-field magnification display
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Virtual bioptic telescope mode
Number of subjects: 88
Study: 38551981

Group type: EXPERIMENTAL
Intervention: Training programme in everyday cognition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional cognitive stimulation
Number of subjects: 0
Study: 38551983

Group type: EXPERIMENTAL
Intervention: High-dose oral thiamine (600-1800 mg daily) for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 36
Study: 38552177

Group type: EXPERIMENTAL
Intervention: Superior approach (SA)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional femoral approach (FA)
Number of subjects: 119
Study: 38552188

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I), 7 weekly virtual sessions
Number of subjects: 132

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 132
Study: 38552197

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg intravenously once every 3 weeks plus cabozantinib 40 mg orally once daily
Number of subjects: 366

Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2
Number of subjects: 366
Study: 38552208

Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SoC)
Number of subjects: 833

Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 833
Study: 38552315

Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (SC-TCZ) treatment
Number of subjects: 82
Study: 38552323

Group type: EXPERIMENTAL
Intervention: Financial and Insurance Navigation Assistance (financial navigation)
Number of subjects: 45
Study: 38552429

Group type: EXPERIMENTAL
Intervention: Baha SoundArc
Number of subjects: 25

Group type: COMPARATOR
Intervention: Baha Softband
Number of subjects: 25
Study: 38552629

Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study: 38552653

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination at 1 year (group 1)
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination at 2 years (group 2)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
Number of subjects: 699
Study: 38552656

Group type: EXPERIMENTAL
Intervention: Trilogy transcatheter heart valve (TAVI)
Number of subjects: 180
Study: 38552659

Group type: COMPARATOR
Intervention: Standard-dose group (10 mg/kg once daily for 4 months)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: 20 mg/kg group (20 mg/kg daily for 2 months)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: 30 mg/kg group (30 mg/kg daily for 2 months)
Number of subjects: 1368
Study: 38553053

Group type: EXPERIMENTAL
Intervention: ACTing Minds video game intervention
Number of subjects: 36
Study: 38553055

Group type: EXPERIMENTAL
Intervention: Point-of-care tests (POCTs) including phase-contrast microscopy and urinary dipsticks for detecting bacteria and erythrocytes in urine samples.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 20
Study: 38553057

Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Environmental strategies
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combined (financial incentives and environmental strategies)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 38553062

Group type: EXPERIMENTAL
Intervention: Personalised prehabilitation programme including coached, supervised or self-directed physical activity and weekly dietary follow-up.
Number of subjects: 50
Study: 38553291

Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text message invitation strategy with pre-alert message
Number of subjects: 88820

Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text message invitation strategy without pre-alert message
Number of subjects: 88820

Group type: COMPARATOR
Intervention: Control (current practice) text message
Number of subjects: 88820
Study: 38553461

Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VST) from partially-HLA matched donors
Number of subjects: 1
Study: 38553525

Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ or cAd3-EBO prime followed by MVA-EbolaZ boost
Number of subjects: 230
Study: 38553594

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT) followed by neoadjuvant consolidation chemotherapy (NCCT)
Number of subjects: 46
Study: 38553602

Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pacifier with 25% dextrose
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 38553649

Group type: EXPERIMENTAL
Intervention: WFPB dietary intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study: 38553674

Group type: EXPERIMENTAL
Intervention: Handmade ultrasound-guided phantom for paracentesis training
Number of subjects: 50
Study: 38553680

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (12 cycles every 2 weeks)
Number of subjects: 312

Group type: COMPARATOR
Intervention: mFOLFOX 6 (12 cycles every 2 weeks)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 312

Group type: COMPARATOR
Intervention: mFOLFOX 6
Number of subjects: 312
Study: 38553690

Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) training combined with 10 hours' time-restricted eating (TRE) for 12 weeks
Number of subjects: 24
Study: 38553746

Group type: EXPERIMENTAL
Intervention: Device feedback only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Device feedback plus parent communication training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 38553749

Group type: EXPERIMENTAL
Intervention: ICU survivors
Number of subjects: 590

Group type: COMPARATOR
Intervention: Non-ICU-treated controls
Number of subjects: 590
Study: 38553950

Group type: EXPERIMENTAL
Intervention: WES/RNA-Seq
Number of subjects: 50

Group type: COMPARATOR
Intervention: TGP/aCGH
Number of subjects: 50
Study: 38553990

Group type: EXPERIMENTAL
Intervention: Postoperative DOTATATE PET/MRI
Number of subjects: 27
Study: 38554013

Group type: EXPERIMENTAL
Intervention: 10-week online fall prevention intervention (weekly virtual group discussions, individual phone check-ins, home exercises)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study: 38554156

Group type: EXPERIMENTAL
Intervention: Ezabenlimab 240 mg
Number of subjects: 117
Study: 38554232

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily (QD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg QD
Number of subjects: 0
Study: 38554563

Group type: EXPERIMENTAL
Intervention: Single IV R-KET administration
Number of subjects: 3
Study: 38554570

Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG) combined with intravenous pembrolizumab
Number of subjects: 18
Study: 38554618

Group type: EXPERIMENTAL
Intervention: Brief video intervention
Number of subjects: 1405

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 1405
Study: 38554717

Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg on day 1) plus P-GEMOX (pegaspargase 2000 U/m2, gemcitabine, and oxaliplatin)
Number of subjects: 34
Study: 38554715

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 38554726

Group type: EXPERIMENTAL
Intervention: Subretinal injection of RGX-314 (dose range 3 × 10)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Subretinal injection of RGX-314
Number of subjects: 68
Study: 38554725

Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel), single intravenous dose (transduced dose range 1·0 × 10)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel)
Number of subjects: 52
Study: 38554817

Group type: EXPERIMENTAL
Intervention: Image-assisted Abrams needle pleural biopsy (IA-ANPB) in Group 1
Number of subjects: 228

Group type: COMPARATOR
Intervention: Medical Thoracoscopy (MT) in Group 1
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Image-assisted Abrams needle pleural biopsy (IA-ANPB) in Group 2
Number of subjects: 228

Group type: COMPARATOR
Intervention: Medical Thoracoscopy (MT) in Group 2
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Complications rate for IA-ANPB
Number of subjects: 228

Group type: COMPARATOR
Intervention: Complications rate for MT
Number of subjects: 228
Study: 38554938

Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 38555057

Group type: EXPERIMENTAL
Intervention: Fluid-filled pressure guidewires
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sensor-tipped pressure guidewires
Number of subjects: 50
Study: 38555079

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1902

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1902
Study: 38555240

Group type: EXPERIMENTAL
Intervention: Machine learning model using Extreme Gradient Boost algorithm
Number of subjects: 6282
Study: 38555253

Group type: EXPERIMENTAL
Intervention: Plasma NPY levels above median (70 pg/ml)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Plasma NPY levels above median (70 pg/ml) after 4 months
Number of subjects: 260
Study: 38555285

Group type: EXPERIMENTAL
Intervention: CHK1 inhibitor prexasertib (CHK1i) in cohort 5
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CHK1 inhibitor prexasertib (CHK1i) in cohort 6
Number of subjects: 49
Study: 38555307

Group type: EXPERIMENTAL
Intervention: Ultra-trail race (156-km)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Post-race period (48-h)
Number of subjects: 55
Study: 38555311

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, lenalidomide and rituximab (R2A)
Number of subjects: 66
Study: 38555336

Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 3920

Group type: EXPERIMENTAL
Intervention: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Number of subjects: 3920

Group type: EXPERIMENTAL
Intervention: Katz activities of daily living (ADL) score
Number of subjects: 3920

Group type: EXPERIMENTAL
Intervention: 6-month mortality
Number of subjects: 3920

Group type: EXPERIMENTAL
Intervention: Age and frailty
Number of subjects: 3920
Study: 38555417

Group type: EXPERIMENTAL
Intervention: Pre-trained model mn30_as
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Male model mn30_as
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Female model mn30_as
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Female model mn4.0
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Other models (pre-trained; mn40_as, non-pre-trained; mn4.0 and mn3.0)
Number of subjects: 198
Study: 38555718

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1.5-2 mg/kg/day orally for 6 weeks)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 108